140 related articles for article (PubMed ID: 35817000)
21. Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H; Kissick HT; Carthon BC; Akce M; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; El-Rayes BF; Ramalingam SS; Owonikoko TK; Harvey RD; Master VA
Oncologist; 2020 Mar; 25(3):e528-e535. PubMed ID: 32162807
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis.
March C; Omari J; Thormann M; Pech M; Wienke A; Surov A
Clin Nutr ESPEN; 2022 Jun; 49():103-113. PubMed ID: 35623801
[TBL] [Abstract][Full Text] [Related]
24. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
25. Low skeletal muscle mass in cholangiocarcinoma treated by surgical resection. A meta-analysis.
Surov A; Pech M; Omari J; Melekh B; March C; Perrakis A; Wienke A
HPB (Oxford); 2022 Jul; 24(7):997-1006. PubMed ID: 34906379
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review.
Shachar SS; Williams GR; Muss HB; Nishijima TF
Eur J Cancer; 2016 Apr; 57():58-67. PubMed ID: 26882087
[TBL] [Abstract][Full Text] [Related]
27. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
28. Skeletal muscle is prognostic in resected stage III malignant melanoma.
Youn S; Eurich DT; McCall M; Walker J; Smylie M; Sawyer MB
Clin Nutr; 2022 May; 41(5):1066-1072. PubMed ID: 35397311
[TBL] [Abstract][Full Text] [Related]
29. The influence process of sarcopenia on female cancer: A systematic review and meta-analysis.
Li YX; Xia WW; Liu WY
J Obstet Gynaecol Res; 2021 Dec; 47(12):4403-4413. PubMed ID: 34496449
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of computed tomography-based sarcopenia and the prognostic value of skeletal muscle index and muscle attenuation amongst women with epithelial ovarian malignancy: A systematic review and meta-analysis.
Tranoulis A; Kwong FLA; Lakhiani A; Georgiou D; Yap J; Balega J
Eur J Surg Oncol; 2022 Jul; 48(7):1441-1454. PubMed ID: 35260290
[TBL] [Abstract][Full Text] [Related]
31. Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma.
Sheth M; Ko J
Cancer Treat Res Commun; 2021; 26():100272. PubMed ID: 33338851
[TBL] [Abstract][Full Text] [Related]
32. High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.
Bastholt L; Svane IM; Bjerregaard JK; Herrstedt J; Hróbjartsson A; Schmidt H
Eur J Cancer; 2019 Jul; 115():61-67. PubMed ID: 31108244
[TBL] [Abstract][Full Text] [Related]
33. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
[TBL] [Abstract][Full Text] [Related]
34. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
[TBL] [Abstract][Full Text] [Related]
35. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.
Naik GS; Waikar SS; Johnson AEW; Buchbinder EI; Haq R; Hodi FS; Schoenfeld JD; Ott PA
J Immunother Cancer; 2019 Mar; 7(1):89. PubMed ID: 30922394
[TBL] [Abstract][Full Text] [Related]
36. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.
Daly LE; Power DG; O'Reilly Á; Donnellan P; Cushen SJ; O'Sullivan K; Twomey M; Woodlock DP; Redmond HP; Ryan AM
Br J Cancer; 2017 Jan; 116(3):310-317. PubMed ID: 28072766
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma.
Klebaner D; Saddawi-Konefka R; Finegersh A; Yan CH; Califano JA; London NR; Deconde AS; Faraji F
Int Forum Allergy Rhinol; 2020 Sep; 10(9):1087-1095. PubMed ID: 32623838
[TBL] [Abstract][Full Text] [Related]
38. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of melanoma patients treated with PD-1 inhibitors: Protocol for an overview, and a network meta-analysis of randomized controlled trials.
Li J; Shi SZ; Wang JS; Liu Z; Xue JX; Wang JC; Jia JH
Medicine (Baltimore); 2019 Jul; 98(27):e16342. PubMed ID: 31277189
[TBL] [Abstract][Full Text] [Related]
40. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
